Fig. 2

In vitro evaluations of anti-vaccinia and anti-MPXV activities of BCV and the candidate compounds. Vero cells were infected with vaccinia Tiantan strain (a) or MPXV (b) and treated with the indicated concentrations of BCV or the candidate prodrugs. All compounds were tested in triplicated wells at each concentration. The solvent was used as the non-treated control. The antiviral effects were determined by calculating the reduction in plaque formation. Data are presented as mean ± SD